Skip to main content

View full-text article in PMC

. 2020 May 12;8:e9052. doi: 10.7717/peerj.9052

Table 2. Association between EZH2/H3K27Me3 to clinical pathological features in ovarian cancer by IHC-score stratification.^a.

Clinicopathological Features	EZH2^high/H3K27Me3^high		EZH2^high/H3K27Me3^low		EZH2^low/H3K27Me3^high		EZH2^low/H3K27Me3^low		P
	N	(100%)	N	(100%)	N	(100%)	N	(100%)
Age (years)^b	16	100	14	100	13	100	11	100	0.312
<50	9	56.25	4	28.57	7	53.85	3	27.27
≥50	7	23.75	10	71.43	6	46.15	8	72.73
Histology	16	100	14	100	13	100	11	100	0.447
Serous	12	75.00	12	85.71	12	92.31	9	81.82
Others	4	25.00	2	14.29	1	7.96	2	18.18
FIGO stage	16	100	14	100	13	100	11	100	0.537
I–II	3	18.75	4	28.57	4	30.77	3	27.27
III–IV	13	81.25	10	71.43	9	69.23	8	72.73
Tumor type	16	100	14	100	13	100	11	100	0.682
Type I	5	31.25	2	14.29	2	15.38	3	27.27
Type II	11	68.75	12	85.71	11	84.62	8	72.73
Chemo response	16	100	13	100	13	100	11	100	0.057
Sensitive	10	62.50	8	61.54	4	30.77	11	100
Resistant	6	37.50	5	38.46	9	69.23	0	0

Notes.

^a

The median IHC score was chosen as the cut-offs for pEZH2, pAkt1 and H3K27Me3.

^b

Age at surgery.

P values were calculated by Kruskal–Wallis test.